Pfizer is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach ...

The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

From STAT’s Matthew Herper: Pfizer said this morning that it would stop development of danuglipron, its experimental oral GLP ...